Annual report pursuant to Section 13 and 15(d)

Acquisition - Narrative (Details)

v3.19.1
Acquisition - Narrative (Details)
 1 Months Ended 2 Months Ended 3 Months Ended 8 Months Ended 10 Months Ended 12 Months Ended 39 Months Ended 63 Months Ended
Sep. 24, 2018
USD ($)
therapy
milestone
$ / shares
shares
Feb. 16, 2018
USD ($)
Nov. 17, 2017
USD ($)
shares
Dec. 31, 2017
USD ($)
$ / shares
Mar. 31, 2018
USD ($)
Dec. 31, 2018
USD ($)
$ / shares
Jun. 30, 2018
USD ($)
Sep. 30, 2018
USD ($)
Sep. 30, 2018
USD ($)
Dec. 31, 2018
USD ($)
$ / shares
Dec. 31, 2017
USD ($)
$ / shares
Dec. 31, 2021
USD ($)
Dec. 31, 2023
USD ($)
Aug. 17, 2018
$ / shares
Dec. 31, 2016
USD ($)
Business Acquisition [Line Items]                              
Common stock, par value (in dollars per share) | $ / shares $ 0.001     $ 0.001   $ 0.001       $ 0.001 $ 0.001     $ 0.001  
Issuance of common stock in TRx acquisition                   $ 19,971,554 $ 5,858,955        
Useful life (in years)                   9 years 4 months 28 days 10 years 18 days        
Debt assumed in Avadel Pediatric Products acquisition       $ 0   $ (15,075,000)       $ (15,075,000) $ 0        
Goodwill       14,292,282   16,411,123       16,411,123 14,292,282       $ 0
Impairment of intangible assets                   1,861,562 0        
Cost of product sales                   7,478,262 635,648        
Avadel                              
Business Acquisition [Line Items]                              
Cash   $ 1                          
Debt assumed in Avadel Pediatric Products acquisition   (15,075,000)                          
Contingent consideration   7,900,000                          
Goodwill   $ 3,778,001                          
Goodwill tax deductible period   15 years                          
Inventory         $ 300,000   $ (1,831,000)                
Fair value of consideration transferred   $ 1                          
Cost of product sales               $ 100,000              
TRx                              
Business Acquisition [Line Items]                              
Issuance of common stock in TRx acquisition                   0 $ 5,858,955        
Cash     $ 18,900,000                        
Contingent consideration     1,366,633                        
Goodwill     $ 12,633,122                        
Inventory       $ 200,000         $ 0            
Unregistered shares of common stock issued or issuable as part of acquisition (in shares) | shares     7,534,884                        
Shares issued for purchase of business (in shares)     $ 8,514,419                        
Shares issued upon closing (in shares) | shares     5,184,920                        
Contingent shares issuable as part of acquisition (in shares) | shares     2,349,968                        
Goodwill, expected tax deductible amount     $ 8,700,000                        
Fair value of consideration transferred     $ 28,781,052                        
Cost of product sales                   200,000          
General and administrative | Avadel                              
Business Acquisition [Line Items]                              
Transaction costs           100,000       $ 100,000          
Acquired Assembled Workforce                              
Business Acquisition [Line Items]                              
Useful life (in years)                   1 year 9 months          
PAI Sales & Marketing Agreement                              
Business Acquisition [Line Items]                              
Useful life (in years)                     1 year 10 months 24 days        
Fair value of sales and marketing agreement           0       $ 0          
PAI Sales & Marketing Agreement | TRx                              
Business Acquisition [Line Items]                              
Useful Life     2 years                        
Acquired Product Marketing Rights                              
Business Acquisition [Line Items]                              
Useful life (in years)                   9 years 5 months 12 days 11 years 2 months 12 days        
Metafolin | Acquired Product Marketing Rights | TRx                              
Business Acquisition [Line Items]                              
Useful Life     15 years                        
Millipred | Acquired Product Marketing Rights | TRx                              
Business Acquisition [Line Items]                              
Useful Life     4 years                        
Nonrecurring | Level 3 | PAI Sales & Marketing Agreement | TRx                              
Business Acquisition [Line Items]                              
Fair value of sales and marketing agreement           0       $ 0          
Ichorion                              
Business Acquisition [Line Items]                              
Consideration issued (in shares) | shares 5,800,000                            
Contingent consideration $ 15,000,000                            
Payment for contingent consideration           0                  
Issuance of common stock in TRx acquisition 20,000,000                            
Intangible assets $ 18,700,000                            
Number of preclinical therapies | therapy 3                            
Cash acquired $ 1,600,000                            
Transaction costs $ 200,000                            
Number of contingent consideration milestones | milestone 3                            
Ichorion | Acquired Assembled Workforce                              
Business Acquisition [Line Items]                              
Intangible assets $ 200,000                            
Useful life (in years) 2 years                            
Milestone One | TRx                              
Business Acquisition [Line Items]                              
Contingent consideration     $ 3,000,000     0       0          
Milestone Two | TRx                              
Business Acquisition [Line Items]                              
Contingent consideration     2,000,000     900,000       900,000          
Milestone Three | TRx                              
Business Acquisition [Line Items]                              
Contingent consideration     $ 2,000,000     $ 400,000       $ 400,000          
Scenario, Forecast | Milestone One | Ichorion                              
Business Acquisition [Line Items]                              
Payment for contingent consideration                       $ 6,000,000      
Scenario, Forecast | Milestone Two | Ichorion                              
Business Acquisition [Line Items]                              
Payment for contingent consideration                       $ 5,000,000      
Scenario, Forecast | Milestone Three | Ichorion                              
Business Acquisition [Line Items]                              
Payment for contingent consideration                         $ 4,000,000